IM Cannabis

IMCC

Market cap $8.81M

TORONTO and GLIL YAM, Israel , Oct. 23, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ: IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced the signing of a non-binding indicative term sheet for a proposed securities exchange agreement to acquire a 60% equity interest in a pioneering quantum computing bio data company ("The Target Company") for aggregate consideration of up to $54 million. The Target Company specializes in utilizing quantum computing principles to store, manipulate, and analyze BIO data more efficiently than current technologies, offering groundbreaking advancements in biological data processing and analytics.

TORONTO and GLIL YAM, Israel , Sept. 16, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced the following changes to its Board of Directors (the "Board").

TORONTO and GLIL YAM, Israel , Sept. 5, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ: IMCC) (the "Company", "IM Cannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, today announced that it received notice from Nasdaq on September 4, 2025 that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,000.

TORONTO and GLIL YAM, Israel , Aug. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ: IMCC), a leading medical cannabis company with operations in Israel and Germany, announces that it has agreed with holders (each, a "Holder") of common share purchase warrants ("November 2024  Warrants") issued by the Company as part of its non-brokered private placement offering which closed on November 12, 2024 to: (x) reduce the exercise price of each November 2024 Warrant from C$4.32 to C$3.43; and (y) extend the expiration date of each November 2024 Warrant from November 12, 2026 to July 31, 2030 (together, the "Transaction"). Form F-3 Resale Registration Statement The Company also announces that, further to its press release dated July 31, 2025 (the " July 31 Release"), it has filed a resale registration statement on Form F-3 (the "Resale Registration Statement") with the Securities and Exchange Commission (the "SEC").

IMC Delivers Strong Profit and Margin Growth Despite Revenue Impact from External Challenges in Q2 2025 TORONTO and GLIL YAM, Israel , Aug. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2024, unless otherwise stated.

TORONTO and GLIL YAM, Israel , Aug. 4, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2025 ended June 30, 2025, on Tuesday, August 12, 2025, before the market opens.   About IM Cannabis Corp. IMC (Nasdaq: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets.

TORONTO and GLIL YAM, Israel , July 31, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that, effective July 30, 2025 (the "Closing Date") it has closed a private placement offering (the "Offering"), through the issuance of 2,050,000 units (each a "Unit") at a price per Unit of C$2.7427 for gross proceeds of C$5,622,522, approximately US$4,100,000, based on an exchange rate of US$1.0000:C$1.3713 as of July 21, 2025, as published on the website of the Bank of Israel (the "Exchange Rate"). Each Unit consisted of one common share in the capital of the Company (each, a "Common Share"), or one pre-funded Common Share purchase warrant (each, a "Pre-Funded Warrant") in lieu thereof, and one Common Share purchase warrant (each, a "Warrant").

TORONTO and GLIL YAM, Israel , July 11, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce the filing and effectiveness of a shelf registration statement (the "Shelf Registration") on Form F-3 with the Securities and Exchange Commission ("SEC"). The Shelf Registration will allow the Company to offer and sell, from time to time, up to an aggregate of $50 million of its common shares, warrants, units, or a combination thereof (together, the "Securities"), on a registered basis, subject to market conditions, the Company's capital needs, and limitations imposed by SEC rules and applicable securities laws.

TORONTO and GLIL YAM, Israel, July 9, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Oz Adler has been appointed to the Company's board of directors (the "Board"), effective July 6, 2025.

TORONTO and GLIL YAM, Israel , July 1, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ: IMCC) (the "Company", "IM Cannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, today announced the following corproate updates.   As previously reported on April 11, 2025, the Company received a deficiency letter (the "Nasdaq Letter") on April 9, 2025 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (the "Nasdaq") notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders' equity for continued listing on the Nasdaq Capital Market (the "Stockholders' Equity Requirement"), nor is it in compliance with either of the alternative listing standards, market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years.